Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Ovarian Neoplasms 104Breast Neoplasms 76Fallopian Tube Neoplasms 47Multiple Myeloma 32Carcinoma, Ovarian Epithelial 27Neoplasms 23Lymphoma 16Sarcoma 13Triple Negative Breast Neoplasms 12Recurrence 12Neoplasm Metastasis 12Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Non-Hodgkin 8Hodgkin Disease 8Neoplasms, Plasma Cell 6Prostatic Neoplasms 5Burkitt Lymphoma 5Solid Tumors 4Sarcoma, Kaposi 4Sarcoma, Ewing 4Pancreatic Neoplasms 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Leiomyosarcoma 4Endometrial Neoplasms 4Carcinoma 4Breast Neoplasms, Male 4Uterine Cervical Neoplasms 3Rhabdomyosarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Doxorubicin 9Imatinib Mesylate 6pazopanib 4Ifosfamide 4Radiotherapy 3Gemcitabine 3Docetaxel 3pembrolizumab 2Radiation 2Neoadjuvant Therapy 2Mohs Surgery 2Biopsy 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2selinexor 1saracatinib 1sapanisertib 1ribociclib 1peposertib 1liposomal doxorubicin 1indolepropanol phosphate 1envafolimab 1cixutumumab 1brigimadlin 1avelumab 1X-Rays 1Watchful Waiting 1TTI-621 1Sunitinib 1Specimen Handling 1Razoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dermatofibrosarcoma × liposomal doxorubicin × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡